Biologics don’t up risk of cancer recurrence

Rheumatoid arthritis patients with a previous cancer diagnosis face no increased risk of recurrence TND inhibitor medications or rituximab, a study has found.

In fact, cancer survivors on TNF inhibitors had a 55% lower risk of developing a malignancy during treatment, compared to those on conventional DMARDs only.

And those on rituximab had a 43% lower risk of recurrence than those on conventional treatments.